St. Walburga Foerdergesellschaft mbH
- Address
- Schederweg 12, 59870 Meschede, Germany
St. Walburga Foerdergesellschaft mbH - Colorectal Cancer Research
St. Walburga Foerdergesellschaft mbH is a medical research center specializing in gastrointestinal oncology, with particular expertise in colorectal cancer management. The center focuses on advancing treatment strategies for early-stage colorectal malignancies through innovative clinical research and precision medicine approaches.
- Adjuvant therapy optimization for UICC stage II colon and rectal cancer
- Circulating tumor DNA (ctDNA) biomarker research for disease monitoring
- Disease-free survival outcomes in early-stage colorectal cancer patients
The center is actively engaged in the CIRCULATE study, which represents a cutting-edge approach to personalized adjuvant therapy decisions. This research investigates whether patients with UICC stage II colon cancer who test positive for circulating tumor DNA (ctDNA) after primary tumor resection benefit from adjuvant chemotherapy, potentially revolutionizing treatment paradigms by using molecular biomarkers to guide clinical decision-making and improve patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Walburga Foerdergesellschaft mbH
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Therapy with Capecitabine in Stage II Colon and Rectal Cancer Patients with ctDNA Positivity Post-Resection | Technische Universitat Dresden | Phase III | Not Recruiting | Dec 2019 | Jan 2026 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 1 | Unknown | 2019-12-04 | 2019-12-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.